While cabozantinib received FDA approval for treatment of MTC (207), ongoing clinical trials aim to assess cabozantinib safety and efficacy in RET fusion-positive NSCLC (NCT01639508, NCT04131543). Here, RET is linked to non-small cell lung carcinoma.